Search Results
Your search for ,OUr matches 10724 pages
Showing 7151 - 7200Mixed Results With Hypofractionated vs Conventional Radiotherapy for Localized Prostate Cancer
Investigators of two European phase III trials have reached different conclusions on whether hypofractionated radiotherapy should replace conventional radiotherapy as a new standard of treatment in localized prostate cancer. The CHHiP trial findings favoring hypofractionation were reported by David ...
Neoadjuvant Chemotherapy May Render Advanced Ovarian Cancers Responsive to Immunotherapy
Although most patients with advanced ovarian cancer initially respond to platinum-based chemotherapy, they usually relapse. According to a study by Frances R. Balkwill, PhD, Professor of Cancer Biology at Barts Cancer Institute, Queen Mary University of London, United Kingdom, and colleagues...
Andrew L. Kung, MD, PhD, Named Chairman of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center
Andrew L. Kung, MD, PhD, has been named the new Chairman of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center (MSK). Dr. Kung most recently served as the Chief of the Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation at NewYork–Presbyterian/Morgan...
ASH and LLS Announce AML Awareness and Education Collaboration
The American Society of Hematology (ASH) and the Leukemia & Lymphoma Society (LLS) are teaming up to raise awareness and provide education about the need for new treatments for acute myeloid leukemia (AML). AML is a complex group of approximately 20 different types of blood cancers with a very...
Prevention Needed to Stem Global Rise in Human Papillomavirus–Related Anal Cancer
The incidence rate of human papillomavirus (HPV)-related anal cancer and its precursor lesion, anal intraepithelial neoplasia, is rising in the United States and globally. Although 5-year survival rates in localized disease are generally favorable, survival in metastatic disease remains poor,...
A Concerned Physician Reflects on Today’s Doctor-Patient Relationship
Doctoring isn’t what it used to be. Like many other professions, it has gone through a multitude of changes ostensibly to improve efficiencies and lower costs. The digital age has reshaped clinical practice from the front office to the exam room. And with the advent of electronic health records...
Managing Upper Extremity Dysfunction in Breast Cancer Survivors
With an increased number of breast cancer survivors and patients with metastatic disease living longer, it is imperative for oncology care providers to manage issues of new and chronic upper extremity dysfunction as a result of the malignancy itself or its treatment. As one of my patients...
Complexities in the Diagnosis and Management of Amyloidosis
Question 1: What is the next best step for this patient? Correct Answer: C. Determination of amyloid subtype. Expert Perspective Amyloidosis encompasses a heterogeneous group of diseases bound by the characteristic deposition of amyloid fibrils in soft tissues and bone marrow, and it could be...
Four NCI-Designated Cancer Centers Collaborate to Establish Research Consortium
The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have...
Fentanyl Nasal Spray Now Available at a Dose of 300 μg for Treatment of Breakthrough Cancer Pain
Fentanyl (Lazanda) nasal spray, a schedule II narcotic, is now available at a 300-μg dose to treat breakthrough cancer pain, offering physicians another titration option for dosing flexibility. The new strength can help physicians more easily and accurately target the appropriate dose for...
HOX Gene Expression in Ovarian Cancer Offers Novel Prognostic Significance
A new study has identified a gene signature that predicts poor survival from ovarian cancer. The study also identified genes which help the cancer develop resistance to chemotherapy—offering a new route to help tackle the disease. The study, published by Kelly et al in the International...
Relapse of Leukemia After Bone Marrow Transplantation: Cytomegalovirus Infection Has No Protective Effect
Recent studies on a small number of patients with leukemia treated with bone marrow transplantation have suggested that the presence of the common cytomegalovirus (CMV) in patients or their donors may protect against relapse or even death after the transplant. A large international study published...
Comparison of Chemotherapy Regimens After Negative Interim PET-CT in Advanced Hodgkin Lymphoma
In a phase III trial reported in The New England Journal of Medicine, Johnson et al found similar efficacy with continued ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy vs omission of bleomycin (AVD) after negative interim PET-CT (positron-emission tomography–computed...
ASCO Announces New Award Honoring Visionary Leader Allen S. Lichter, MD, FASCO
At the end of June, Allen S. Lichter, MD, FASCO, retired after serving as ASCO’s Chief Executive Officer (CEO) for 10 years. To honor his commitment and contributions to ASCO and recognize his lasting impact on the field of oncology, the Society has created a new Special Award, the Allen S. Lichter ...
Regarding Beau
Like most pediatric hematologists/oncologists, my career has been a journey, hoping to discover ways to improve the outcomes for children and adolescents with cancer. I have been blessed to work with outstanding colleagues in the United States and throughout the world. And of equal importance, I...
ASCO Names Founding Editor-in-Chief of JCO Precision Oncology
ASCO recently announced the appointment of James M. Ford, MD, as Editor-in-Chief of the Society’s new journal, JCO Precision Oncology. Dr. Ford will set the scope and vision for the online-only journal, which will publish scientific and educational content that provides a deeper understanding of...
What’s Driving the Rising Rates of Colorectal Cancer in Young Adults?
The study statistics are alarming—and perplexing. According to an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) colorectal cancer registry, colon cancer incidence among young adults aged 20 to 34 is expected to increase 90% by 2030, and the incidence of rectosigmoid...
Personalized Dosimetry Optimizes Radiotherapy Dose in Patients With Neuroendocrine Tumors
Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented a molecular imaging methodology that allows the increase of the radiotherapy dose to the tumor while protecting vulnerable vital organs.1 The delicate balance of administering the...
Computed Tomography–Based Lean Body Mass Calculations May Improve Accuracy of PET for Patients With Cancer
Patients with cancer often experience significant fluctuations in weight and lean body mass. Neglecting to account for these changes can prevent clinicians from obtaining precise data from molecular imaging, but a new method of measuring lean body mass takes changes in individual body composition...
Novel Approach to PET/CT Imaging May Predict Location and Extent of Primary Prostate Cancer
With surgical removal at the front line of defense against prostate cancer, oncologists are considering prostate-specific molecular imaging at the point of initial biopsy and preoperative planning to root out the full extent of disease, researchers showed at the 2016 Annual Meeting of the Society...
Mixed Results With Resection of Primary Tumor in Stage IV Breast Cancer
For de novo stage IV breast cancer, does resection of the primary tumor improve outcomes? Two studies presented at the 2016 ASCO Annual Meeting reached different conclusions. A prospective randomized study conducted in Turkey concluded there is a survival benefit at 5 years,1 whereas a U.S....
Pertuzumab-Containing Regimens Compared for Neoadjuvant Treatment in Early Breast Cancer
In patients with HER2-positive early breast cancer, pathologic complete response rates after neoadjuvant therapy were higher with docetaxel plus carboplatin plus trastuzumab (Herceptin) plus pertuzumab (Perjeta), or TCH+P, than with ado-trastuzumab emtansine (Kadcyla) plus pertuzumab, or T-DM1+P,...
EBCTCG Analysis Identifies Recurrence Risk by Tumor Subgroup in Estrogen Receptor–Positive Breast Cancer
The risk of recurrence in estrogen receptor–positive breast cancer is known to continue after 5 years, but just how much is that risk once endocrine therapy is stopped? The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) has concluded it is “appreciable,” with distant recurrences...
The Age of the Atomic Hematologists/Oncologists
Every longstanding culture has ages: The Minoans were followed by the Mycenaeans and, later, the Hellenistic peoples. And so it is with hematology/oncology. A descriptive age dominated predominately by histopathologists was followed by an age of experimentalists. Development of the atomic bombs...
Approximately 20% of Older Women With Early Breast Cancer Experience Some Form of Functional Decline After Treatment
In a study of older women with newly diagnosed stage I to III breast cancer, approximately 1 in 5 lost the ability to complete some of the basic tasks necessary for independent living within 1 year of initiating treatment. The study also found that a simple survey can help identify which women are...
Women With High-Grade Cervical Intraepithelial Neoplasia Have Long-Term Increased Risk for HPV-Related Anal, Vulvar, and Vaginal Cancers
Although high-risk human papillomavirus (HPV) is essential for developing high-grade cervical intraepithelial neoplasia (CIN2 and CIN3) and has also been associated with noncervical anogenital cancers, little is known about the long-term risk for anal, vulvar, and vaginal cancer following a...
At Cancer Moonshot Summit, Vice President Biden Announces New Actions to Accelerate Progress Against Cancer
Today, the Cancer Moonshot hosted a summit at Howard University, in Washington, DC, as part of a national day of action that also included more than 270 events in communities across the United States. Vice President Joe Biden joined over 350 researchers, oncologists, care providers, data and...
NCCN Publishes New Patient Education Resources About Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are the result of genetic alterations that cause blood stem cells to become abnormal, rendering bone marrow unable to create new, mature blood cells for release into the body. It is estimated that up to 15,000 new cases of MDS are diagnosed in the United States each...
CAP, IASLC, and AMP Seek Public Comments on Revised Lung Cancer Molecular Testing Guideline
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised evidence-based guideline, “Molecular Testing Guideline for Selection of...
Influence of Microbiota of Breast Tissue on the Development of Cancers
Bacteria that have the potential to abet breast cancer are present in the breasts of cancer patients, while beneficial bacteria are more abundant in healthy breasts, where they may actually be protecting women from cancer, according to Gregor Reid, PhD, of the Lawson Health Research Institute, and...
Nivolumab Receives FDA Breakthrough Therapy Designation for Advanced/Metastatic Urothelial Carcinoma
Bristol-Myers Squibb Company announced June 27 that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to nivolumab (Opdivo) for the potential indication of unresectable locally advanced or metastatic urothelial carcinoma that has progressed on or after a...
Precision Medicine Clinical Trial for Metastatic Pancreatic Cancer Now Open at Multiple Sites
The first clinical trial to compare standard-of-care chemotherapy with molecularly tailored therapy (also known as precision medicine) for metastatic pancreatic cancer is now enrolling patients at multiple sites around the country. Patients who have been treated with one round of chemotherapy for...
Surgery and Radiation Therapy Remain Standard of Care for Managing Ductal Carcinoma in Situ
A review of more than 50 studies (many randomized controlled trials) concluded that surgery and radiation therapy “remain standard-of-care treatment options” in the management of ductal carcinoma in situ.1 The review continues the widely reported discussion on managing ductal carcinoma in situ,...
Something Happened
Over the years, my patients have been my most important teachers. I’ve learned so much from them about human nature and the resilience of the human spirit. When my time came to pass through the fire and confront the same challenges they and their families face so bravely and with such compassion, ...
Inside Knowledge From a Cancer Survivor
Curtis Pesmen is a well-regarded writer who has authored six books of nonfiction as well as numerous articles for publications such as Esquire and The New York Times. He also has served as founding editor of LIVESTRONG Quarterly and often speaks and writes on patient advocacy. Shortly after...
Newly Launched Genomic Data Commons to Facilitate Data and Clinical Information Sharing
The Genomic Data Commons (GDC), a unified data system that promotes sharing of genomic and clinical data among researchers, was launched on June 6 with a visit from Vice President Joe Biden to the operations center at the University of Chicago. An initiative of the National Cancer Institute (NCI),...
St. Jude Children’s Research Hospital Names Michael Dyer, PhD, Chair of Developmental Neurobiology
St. Jude Children’s Research Hospital has named Michael Dyer, PhD, Chair of the Department of Developmental Neurobiology. “A true visionary in his field, Dr. Dyer is a remarkable scientist who has worked tirelessly to unravel some of the long-held mysteries of childhood cancer,” said James R....
Moonshot Program for … Compassion
A 65-year-old patient with widely metastatic pancreatic cancer was emergently transferred to our facility in the early hours of the morning with free air suggestive of a perforated viscus. The patient is from a small town several hundred miles away from our academic center, which can be quite...
Clinical Trials Actively Recruiting Patients With Ocular Cancer
Phase 0 Study Title: Use of Definity® Contrast Agent for Ultrasound of Intraocular Tumors Study Type: Interventional/single-group assignment Study Sponsor and Collaborators: Emory University Purpose: To determine if microbubbles may be used as a contrast agent to help image tumors in the eye. In...
Katherine L. Nathanson, MD, Receives AACR’s Frohlich Visiting Professorship
Katherine L. Nathanson, MD, Professor of Medicine in the Division of Translational Medicine and Human Genetics at the Perelman School of Medicine of the University of Pennsylvania, has received the 2015 Frohlich Visiting Professorship through the American Association for Cancer Research (AACR)....
Vanguard Practices Support Sharing Big Data With CancerLinQ™
CancerLinQ LLC, recently announced that it has completed agreements with 36 vanguard oncology practices from around the country to begin implementing the tool. According to physicians at the vanguard practices, gaining access to the experience of oncology practices across the country motivated...
Clinical Conversations: Attendee Questions From the Cancer Survivorship Symposium
The inaugural Cancer Survivorship Symposium, held in January 2016, drew more than 800 attendees across the cancer-care spectrum—far exceeding the goal of 500 attendees. As a way to continue the discussion from the meeting, several faculty members responded to questions from General Sessions 5 and...
ASCO Endows Young Investigator Award in Honor of Society Founder Jane Cooke Wright, MD
For the first time in ASCO’s history, the Society has endowed its own Young Investigator Award (YIA), illustrating its continued commitment to investing in the future of cancer research. Ongoing support of this kind will ensure that the Conquer Cancer Foundation (CCF), ASCO’s philanthropic arm, is...
Geriatric Patients With Cancer and the Problem of Polypharmacy
Older patients with cancer generally have multiple comorbidities, with each often requiring separate medications. Studies have shown that polypharmacy and inappropriate drug use are prevalent among older cancer patients, leading to an enormous amount of preventable adverse events, many requiring...
Nivolumab or Ipilimumab Treatment May Increase Risk of Developing Autoimmune Joint and Tissue Disease
Case reports on 13 patients with cancer suggest that patients taking the immunotherapeutics ipilimumab (Yervoy) and nivolumab (Opdivo) may be at higher-than-normal risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a preliminary study by Johns...
Five Early-Career Cancer Researchers Selected as Pew-Stewart Scholars
The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust have announced the 2016 class of Pew-Stewart scholars for cancer research. Five scientists from top research institutions in the United States were selected for their dedication to pursuing innovative leads aimed at finding a...
Tackling the Symptoms of Long-Term Fatigue and Insomnia in Cancer Survivors
Fatigue and sleep disruption are common occurrences for most patients diagnosed with cancer. Simply having a serious physical illness like cancer along with its associated pain, hospitalization, and treatment, as well as the attendant psychological impact, all contribute to the onset of fatigue...
Cancer Treatment Centers of America Names Rajesh K. Garg, MD, JD, as President and CEO
Cancer Treatment Centers of America Global, Inc. (CTCA) has announced that Rajesh Garg, MD, JD, a highly regarded health-care industry leader with more than 25 years of experience across the health-care spectrum, will become its President and CEO. His appointment was effective June 20, 2016. He...
A Conquer Cancer Foundation Award Helps to Launch a Pioneering Study in Liposarcoma
Mark A. Dickson, MD, has been fascinated by science and medicine since he was in high school. After graduating magna cum laude from Harvard University in 1999, Dr. Dickson pursued a medical degree from the College of Physicians and Surgeons at Columbia University in New York. Once he decided on a...
European Demand for Radiotherapy Expected to Rise Approximately 16% Over Next Decade
The demand for radiotherapy across all European countries will increase by an average of 16% between 2012 and 2025, with the highest expected increase being for prostate cancer cases (24%), according to a new study published by Borras et al in Radiotherapy and Oncology.1 These projections came...
